Supply of products by Bristol-Myers Squibb Australia Pty Ltd

Administered by Department of Health, Disability and Ageing

Legislation au C2013G00991 In force Gazette

Legislation content

 

THERAPEUTIC GOODS ACT 1989

 

SECTION 14 AND 14A NOTICE

 

 

 

On May 22, 2013 the delegate of the Secretary of the Department of Health and Ageing for the purposes of subsection 14 and 14A of the Therapeutic Goods Act 1989 (“the Act”) gave his consent to:

 

(a)   the supply of the products listed in the following table by Bristol-Myers Squibb Australia Pty Ltd MT Waverley, VIC (“the Company”);

 

That do not conform with paragraphs 3(2)(l) of Therapeutic Goods Order (TGO) 69, in that the sponsor address details on the labels are those of the previous address.

 

 

Pursuant to subsection 15(1) of the Act, the consent given by the delegate of the Secretary as described above is subject to the following conditions:

 

  1. The consent to supply applies until the end of December 2013.
  2. The labels to which this consent applies are those currently used for the product, bearing the previous address details, 556 Princes Highway Noble Park Victoria 3174 instead of the new address, 4 Nexus Court, Mulgrave Victoria 3170.
  3. No other changes have been made to the products listed in the following table.
  4. Arrangements are in please so that consumer queries or complaints are promptly forwarded to the new address.


Aust R

Product

90925

aripiprazole (ABILIFY) 5 mg tablet blister pack

90997

aripiprazole (ABILIFY) 10 mg tablet blister pack

90998

aripiprazole (ABILIFY) 15 mg tablet blister pack

91000

aripiprazole (ABILIFY) 30 mg tablet blister pack

14032

aztreonam (AZACTAM) 1g powder for injection vial

116852

entecavir monohydrate (BARACLUDE) 0.5 mg film coated blister pack

116853

entecavir monohydrate (BARACLUDE) 1 mg film coated blister pack

19252

lomustine (CEENU) 10 mg capsule bottle

19249

lomustine (CEENU) 40 mg capsule bottle

19250

lomustine (CEENU) 100 mg capsule bottle

47486

hydroxyurea (HYDREA) 500 mg capsule bottle

19263

fluphenazine decanoate (MODECATE) 12.5mg/0.5 mL injection ampoule

47023

fluphenazine decanoate (MODECATE) 25 mg/1 mL injection ampoule

47024

fluphenazine decanoate (MODECATE) 50 mg/2 mL injection ampoule

68968

fosinopril / hydrochlorothiazide (MONOPLUS) 10 mg/12.5 mg tablets bottle

68970

fosinopril / hydrochlorothiazide (MONOPLUS) 20 mg/12.5 mg tablet bottle

46475

fosinopril (MONOPLUS) 10 mg tablets bottle

46473

fosinopril (MONOPLUS) 20 mg tablets bottle

157907

saxagliptin (as hydrochloride) (ONGLYZA) 5 mg film coated tablet blister pack

99870

paracetamol (PERFALGAN) 500 mg/ 50 mL injection vial

99869

paracetamol (PERFALGAN) 1 g/ 100 mL injection vial

165096

naltrexone hydrochloride (REVIA) 50 mg tablet blister pack

99055

atazanavir (REYATAZ) 150 mg capsule bottle

99056

atazanavir (REYATAZ) 200 mg capsule bottle

134967

atazanavir (REYATAZ) 300 mg capsule bottle

125557

dasatinib (SPRYCEL) 20 mg tablet bottle

125559

dasatinib (SPRYCEL) 50 mg tablet bottle

125561

dasatinib (SPRYCEL) 70 mg tablet bottle

157352

dasatinib (SPRYCEL) 100 mg tablet bottle

78351

didanosine (VIDEX EC) 125 mg capsule bottle

78353

didanosine (VIDEX EC) 200 mg capsule bottle

78355

didanosine (VIDEX EC) 250 mg capsule bottle

78357

didanosine (VIDEX EC) 400 mg capsule bottle

19286

teniposide (VUMON) 50 mg/5mL injection ampoule

54299

stavudine (ZERIT) 20 mg capsule bottle

53400

stavudine (ZERIT) 30 mg capsule bottle

53401

stavudine (ZERIT) 40 mg capsule bottle

 

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.